Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
72
NCT03658772
Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 20, 2018
Completion: Mar 7, 2023
NCT03696212
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Phase: Phase 1/2
Start: Jan 8, 2019
Completion: Feb 15, 2021